Positive Interim Data Published for Transfusion-Dependent Β-Thalassemia Gene Therapy – AJMC.com Managed Markets Network
|
Positive Interim Data Published for Transfusion-Dependent Β-Thalassemia Gene Therapy
AJMC.com Managed Markets Network Kelly Davio. Bluebird bio, Inc, has announced the publication of positive interim data for its gene therapy to eliminate or reduce chronic blood transfusions in patients with transfusion-dependent β-thalassemia. Bluebird bio, Inc, has announced the … |
